A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit.
Latest Information Update: 29 Jul 2019
At a glance
- Drugs Volasertib (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
Most Recent Events
- 20 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jul 2011 Planned end date changed from 1 Jul 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 27 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.